Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

Eradication of HIV from Tissue Reservoirs: Challenges for the Cure

(2018) Rebecca Rose et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics

(2018) Ian Olivier et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Treatment adherence in HIV stigmatized environments in South Africa: stigma avoidance and medication management

(2018) Seth C Kalichman et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations

(2017) Michelli F. Oliveira et al.   PLoS Pathogens

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy

(2016) Albert M. Anderson et al.   JOURNAL OF INFECTIOUS DISEASES

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia

(2016) Sam Nightingale et al.   JOURNAL OF NEUROVIROLOGY

HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads

(2016) Susanna L. Lamers et al.   JOURNAL OF VIROLOGY

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers

(2015) R Verloes et al.   HIV MEDICINE

GSK1265744 Demonstrates Robust In Vitro Activity Against Various Clades of HIV-1

(2015) Sharon L. Karmon et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

(2015) Melinda J. Reese et al.   XENOBIOTICA

Formulation and pharmacology of long-acting rilpivirine

(2015) Peter E. Williams et al.   Current Opinion in HIV and AIDS

Formulation and pharmacology of long-acting cabotegravir

(2015) Christine Trezza et al.   Current Opinion in HIV and AIDS

Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection

(2014) Tomokazu Yoshinaga et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

(2014) S. L. Letendre et al.   CLINICAL INFECTIOUS DISEASES

Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

(2014) Jean B. Nachega et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy

(2014) B. Mora-Peris et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

(2013) W. Spreen et al.   HIV CLINICAL TRIALS

Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro

(2013) Johanna Weiss et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Etravirine in CSF is highly protein bound

(2013) A. Nguyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744

(2012) Susan L. Ford et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Etravirine concentrations in CSF in HIV-infected patients

(2012) J. M. Tiraboschi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antiretroviral drug treatment of CNS HIV-1 infection

(2011) A. Yilmaz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

(2010) D. Croteau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

(2010) B. M. Best et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance

(2009) Edward M Gardner et al.   AIDS

Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1–Infected Individuals

(2009) Aylin Yilmaz et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System

(2008) Scott Letendre   ARCHIVES OF NEUROLOGY